

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**  
**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) May 14, 2008

**SPHERIX® INCORPORATED**

(Exact name of registrant as specified in its charter)

<u>Delaware</u>	<u>0-5576</u>	<u>52-0849320</u>
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
<u>6430 Rockledge Drive, Westmoreland Bldg. #503, Bethesda, MD</u>		<u>20817</u>
(Address of principal executive offices)		(Zip Code)
Registrant's telephone number, including area code	<u>301-897-2540</u>	

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Section 2 – Financial Information.**

**Item 2.02. Results of Operations and Financial Condition.**

On May 14, 2008, the Registrant issued a press release regarding its financial results for the quarter ended March 31, 2008. A copy of the press release is attached hereto as Exhibit 99.1.

The information provided in this Current Report on Form 8-K is being provided pursuant to Item 2.02 of Form 8-K. The information in this report shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by specific reference in such a filing.

**Section 9 – Financial Statements and Exhibits.**

Item 9.01. Financial Statements and Exhibits.

Exhibit 99.1 – Press Release dated May 14, 2008.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Spherix Incorporated  
(Registrant)

**By:**

/s/ Claire L. Kruger  
Claire L. Kruger  
CEO and COO

/s/ Robert L. Clayton  
Robert L. Clayton  
CFO and Treasurer

**Date:** May 14, 2008

**Exhibit 99.1**

For additional information, contact  
Investor Relations, (301) 897-2540  
Email: info@spherix.com

May 14, 2008

**SPHERIX REPORTS 1<sup>ST</sup> QUARTER EARNINGS**

BETHESDA, MD, Spherix Incorporated (NASDAQ/SPEX) reported a net loss for the three months ended March 31, 2008 of \$1.9 million, or \$0.13 per share. During this period, expenditures included \$1 million in R&D on the company's on-going Phase 3 clinical trial in the use of Naturlose for the treatment of Type 2 diabetes. R&D costs for the same period in the prior year were \$1.4 million and reflected the start-up costs for the trial.

	<b>For the Three Months Ended March 31,</b>	
	<b>2008</b>	<b>2007</b>
Revenue from continuing operations	\$ 143,000	\$ -
Loss from continuing operations	\$ (1,914,000)	\$ (2,040,000)
Loss from discontinued operations	\$ -	\$ (251,000)
Net loss	\$ (1,914,000)	\$ (2,291,000)
Net loss per share		
Continuing operations	\$ (0.13)	\$ (0.15)
Discontinued operations	\$ -	\$ (0.02)
Net loss per share	\$ (0.13)	\$ (0.16)

---

Certain statements contained herein are "forward looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied. Factors that could cause actual results to differ materially from those expressed or implied include, but are not limited to, those discussed in filings by the Company with the Securities and Exchange Commission, including the filing on Form 8-K made on October 10, 2007.

Spherix's mission is to create value and increase shareholder wealth through innovations that benefit our clients and the human condition. Spherix offers innovations in biotechnology, and provides technical and regulatory consulting services to biotechnology and pharmaceutical companies.

Our Internet address is <http://www.spherix.com>.

# # # # #